Teresa Gordoa-Alonso

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).

Journal: BMC cancer

Published: June 13, 2026

From Cystectomy to Conservation: Can Perioperative Enfortumab Vedotin Plus Pembrolizumab and Immuno-Radiotherapy Redefine the Standard of Care in Muscle-Invasive Bladder Cancer?

From Cystectomy to Conservation: Can Perioperative Enfortumab Vedotin Plus Pembrolizumab and Immuno-Radiotherapy Redefine the Standard of Care in Muscle-Invasive Bladder Cancer?

Journal: The Journal of urology

Published: April 28, 2026

Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

Re: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer.

Journal: European urology

Published: March 30, 2026

Determinants of physicians' risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancer.

Determinants of physicians' risk-benefit perceptions of adjuvant radioactive iodine for differentiated thyroid cancer.

Journal: Endocrine

Published: March 25, 2026

Immune checkpoint inhibitors for the treatment of cancer in people living with HIV.

Immune checkpoint inhibitors for the treatment of cancer in people living with HIV.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: March 14, 2026

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Real-World outcomes and prognostic factors in anaplastic thyroid cancer: Evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-Thyroid cohort.

Journal: The oncologist

Published: February 27, 2026

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 20, 2026

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Journal: Journal for immunotherapy of cancer

Published: February 02, 2026

Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

Proximal-To-Distal Gradient and Its Implications in Differentiation and Prognosis in Colorectal Neuroendocrine Neoplasms: The RGETNE-HERACLES Study.

Journal: Neuroendocrinology

Published: January 21, 2026

Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?

Journal: The oncologist

Published: January 19, 2026

Showing 1-12 of 127

Last Updated: 09/26/2026